Clinical trial

Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)

Name
16466
Description
The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States. This study is for research purposes only, and is not intended to treat any medical condition. No study therapy(ies) for AD will be administered.
Trial arms
Trial start
2016-10-29
Estimated PCD
2021-01-30
Trial end
2026-04-28
Status
Active (not recruiting)
Treatment
Florbetapir F 18 PET Scan
Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.
Arms:
MCI (Amyloid Negative), MCI (Amyloid Positive), Mild AD Dementia (Amyloid Positive), Mild Dementia (Amyloid Negative)
Other names:
LY3078786
Size
1400
Primary endpoint
Mean Economic Cost Associated with Amyloid Positive AD
Baseline through Study Completion (36 Months)
Eligibility criteria
Inclusion Criteria: * Presents within normal course of outpatient care for whom the physician deems to meet clinical criteria for MCI due to AD or mild AD dementia. * Fully informed written consent of the participant (or his/her legal representative). * Study partner who has frequent contact with the participant is willing to accompany the participant at the study observations. * Fully informed written consent of the study partner; this person must be willing to serve as study partner for at least 6 months of the year. * Able to communicate in English and/or US Spanish. * Able to provide evidence of amyloid testing. * Has an Mini-Mental State Examination (MMSE) score of 20 or greater. Exclusion Criteria: * Are currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study at baseline. * Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. * Lack of evidence of amyloid positivity through pre-study test. Note: After baseline assessment, participants with amyloid negativity identified as part of the study will not continue in post-baseline assessments. * Are Lilly employees or are employees of any third-party organization (TPO) involved in study who require exclusion of their employees.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'enrollmentInfo': {'count': 1400, 'type': 'ESTIMATED'}}
Updated at
2023-10-05

1 organization

1 product

2 indications